Combining the Multitargeted Tyrosine Kinase Inhibitor Vandetanib with the Antiestrogen Fulvestrant Enhances Its Antitumor Effect in Non-small Cell Lung Cancer-Reference-Cited by-同舟云学术

Combining the Multitargeted Tyrosine Kinase Inhibitor Vandetanib with the Antiestrogen Fulvestrant Enhances Its Antitumor Effect in Non-small Cell Lung Cancer

Published:2012-03 Issue:3 Volume:7 Page:485-495
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Siegfried Jill M.,Gubish Christopher T.,Rothstein Mary E.,Henry Cassandra,Stabile Laura P.

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference38 articles.

1. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer;Schiller;N Engl J Med,2002

2. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer;Sandler;N Engl J Med,2006

3. Role of erlotinib in first-line and maintenance treatment of advanced non-small-cell lung cancer;Reguart;Cancer Manag Res,2010

4. New developments in angiogenesis: a major mechanism for tumor growth and target for therapy;Jones;Cancer J Sci Am,1998

Cited by 50 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. SNSynergy: Similarity network-based machine learning framework for synergy prediction towards new cell lines and new anticancer drug combinations;Computational Biology and Chemistry;2024-06

2. Evaluation of Risk Factors for Lung Cancer Among Never Smokers and Their Association With Common Driver Mutations;Cureus;2024-03-12

3. Development of a prognostic model for lung adenocarcinoma polarity‐related genes and analysis of immune landscape;Biotechnology and Applied Biochemistry;2024-03-12

4. Autocrine 17-β-Estradiol/Estrogen Receptor-α Loop Determines the Response to Immune Checkpoint Inhibitors in Non–Small Cell Lung Cancer;Clinical Cancer Research;2023-06-07

5. Prognostic value of CYFRA 21 − 1 and Ki67 in advanced NSCLC patients with wild-type EGFR;BMC Cancer;2023-03-31